Ulcerative colitis is one of inflammatory bowel diseases, and is a government-designated intractable disease. It is reported that there are more than 160,000 patients with ulcerative colitis in Japan. In ulcerative colitis, ulcers develop in the colonic mucosa. Abdominal pain, diarrhea and rectal bleeding strongly decrease the patients’ QOL (quality of life). The cause of disease remains unknown, and there exist merely limited treatments up to the present. Intention of Ajinomoto Pharmaceuticals to concentrate on GI disease area and aim to improve QOL of as many as patients matched Kissei’s portfolio strategy, and the two companies have decided to go into partnership.